Mads Hald Andersen

Medicine & Life Sciences

1. T-Lymphocytes 100%
2. Neoplasms 62%
3. Vaccination 53%
4. Indoleamine-Pyrrole 2,3,-Dioxygenase 51%
5. Melanoma 43%
6. Peptides 35%
7. Vaccines 34%
8. Epitopes 28%
9. Dendritic Cells 28%
10. Immunotherapy 28%
11. Tumor-Infiltrating Lymphocytes 27%
12. Neoplasm Antigens 25%
13. Subunit Vaccines 24%
14. Tumor Microenvironment 24%
15. Arginase 21%
16. Survivin 21%
17. Calreticulin 21%
18. Antigens 17%
19. Cancer Vaccines 17%
20. Regulatory T-Lymphocytes 14%
21. HLA-A2 Antigen 14%
22. Therapeutics 14%
23. Immune System 13%
24. Immunity 13%
25. Ligands 13%
26. Mutation 10%
27. Hematologic Neoplasms 10%
28. Adoptive Transfer 10%
29. Immunosuppressive Agents 9%
30. Cytotoxic T-Lymphocytes 9%
31. Tissue Donors 9%
32. Cutaneous T-Cell Lymphoma 8%
33. Cell- and Tissue-Based Therapy 8%
34. Exons 7%
35. Hereditary Nonpolyposis Colorectal Neoplasms 7%
36. Interleukin-2 7%
37. Cellular Immunity 7%
38. HLA Antigens 7%
39. Clone Cells 7%
40. Proteins 6%
41. staphylococcal alpha-toxin 6%
42. Primary Myelofibrosis 6%
43. B-Cell Lymphoma 6%
44. Antigen-Presenting Cells 6%
45. Cyclin B1 5%
46. Nivolumab 5%
47. Cytokines 5%
48. Survival 5%
49. Enzymes 5%
50. Breast Neoplasms 5%